### **Tropical Disease Initiative**

www.tropicaldisease.org



Marc A. Marti-Renom <a href="http://salilab.org/~marcius">http://salilab.org/~marcius</a>



Depts. of Biopharmaceutical Sciences and Pharmaceutical Chemistry California Institute for Quantitative Biomedical Research University of California at San Francisco

### TDI web site http://www.tropicaldisease.org/



Copyright 2004-2005 TDI, webmaster Ursula Pieper

### TDI TDI wiki site Wiki

### http://nurture.nature.com/wikis/tdi/

FrontPage - Tro	opical Disease Initiative Wiki
🔶 - 🚔 🙆 👔 🙆 http://nurture.nature.com/wikis/tdi/FrontPa	ge 🔻 🔍 🕼 🥵
Tropical Disease Initiative Wiki         FrontPage         RecentChanges         TitleIndex         V	للمعتابة والمعنانين المعالية المعالية معالية المعالية المعال معالية المعالية المعالي
Tropical Disease Initiative	
This website	
This is a wiki, which is a website that anyone can edit and hence contribute to. If <u>WikiSandBox</u> to get an idea of how things work.	you're new to wikis, please take a look at the <u>HelpContents</u> and feel free to play in the
Background	
The Tropical Diseases Initiative (TDI) is	
"a decentralized, community-wide effort that (a) searches parasite genomes for drug?s chances for success, and (d) selects the most promising candidates for furt	r new targets, (b) finds chemicals that bind to known targets, (c) evaluates each candidate ther development."
(Quote taken from  this paper)	
It's currently just an idea. The aim of this wiki is to see if we can turn it into more	a than that, starting with a website.
Below is a list of people who have been invited to contribute to this planning phase	e, followed by some subjects for discussion and related reading.
If you've never used a wiki before, you'll find some helpful links right at the bottor. So if you have something to add, or you don't like what you're reading, please clic	m of this page. The main thing to realise is that you can edit any page (including this one). ck on the "EditText" link at the bottom-left of any page to do something about it.
People	
AndreiSali     ArtiRai     DeclanButter     SteveMaurer     TimoHannay	
Discussions	
Here are some issues to get the ball rolling. Not only don't I have answers, these $(\underline{TimoHannay})$	might not even be the right questions. But you gotta start somewhere. 🐵
ToliAims: What, exactly, is the TDI trying to achieve?     TolPositioning: How does the TDI fit in with other related initiatives? How (i     TolParticipation: Who needs to be involved in TDI for it to succeed in its sta     TolOrganization: Which bits need to be organized and which should be allow     TolWebaite: How could a TDI website support the initiative at this formative     TolActivity: What are some sample problems for TDI volunteers?     Resources	ked alms? wed to emerge? Does TDI need a leader? Wiki is a nince of server software tha
O TDI website	
	page content using any Web browser.

- Fill Important Gap in Existing R&D Efforts.
- Tip Economics.
- Experiment in Open Science.

### http://salilab.org/mailman/listinfo/tdi-discuss

#### **TDI-discuss -- Tropical Disease Initiative discussion forum**

About TDI-discuss			View this page in English (USA)
This list will be for discussing open source drug discovery	efforts for tropical di	eases.	
To see the collection of prior postings to the list, visit the $\underline{I}$	DI-discuss Archives.		
Using TDI-discuss			
To post a message to all the list members, send email to tdi	-discuss@tropicaldis	ase.org.	
You can subscribe to the list, or change your existing subs	cription, in the section	s below.	
Subscribing to TDI-discuss			
Subscribe to TDI-discuss by filling out the following form This is a hidden list, which means that the list of members Your email address:	. You will be sent em is available only to th	ail requesting confirmation, to preven the list administrator.	t others from gratuitously subscribing you
Your name (optional):			
You may enter a privacy password below. This provides only your subscription. Do not use a valuable password as it will			
If you choose not to enter a password, one will be automatic confirmed your subscription. You can always request a mail Once a month, your password will be emailed to you as a rer	back of your password w		
Pick a password:			
Reenter password to confirm:			
Which language do you prefer to display your messages?	English (USA)	<b>_</b>	

Would you like to receive list mail batched in a daily digest?

Subscribe

14 Mar 2005			
I think TDI is a unique and very intere something for it	esting project. I would like so much to make	-	
So, where are we going? What's h	appening? What can we do?		
I still trust in open source drug discov	t, if any, the bott g ideas and poter n Action Plan!	tienecks are? Intial avenues to explore,	
Luca Brivio		]	
9 Mar 2005 I'm a programmer, not something to keep the begin on, I'd be g	ell me wher		
GNU started with RM Thank you kindly, Linux started with Lii Adam Huber You need someone g			
people start sending patches			
I know this is chicken-egg, but someone r in the papers or the website.	eeds to point this out, since I haven't seen this broken the seen this broken the seen this broken the seen the	ought up	
	pios.net effort mentioned already. Together, you ju ff. Consider this like when people jumped off the H vork.		ic that the
Daniel Amelang			
	Stephen Wark Waurer	i	

14 Mar 2005						
I think TDI is a unique and something for it	very interesting proje	16 Feb 2005				
So, where are we going?	What's happening?	Hi,				
I still trust in open source d	rug discovery. :-))	It would be interesting to know what, if any, the bottlenecks are? The Wiki site contains many interesting ideas and potential avenues to explore,				
Luca Brivio		but from what I can see it is lacking an Action				
9 Mar 2005 however, I'm a programmer, not <b>If some</b>	one will tell me wher	Jacob Lester				
something to keep the begin or						
GNU started with RM Thank yo Linux started with Lin Adam Hu You need someone g people start sending patches.	uber					
I know this is chicken-egg, but someone needs to point this out, since I haven't seen this brought up in the papers or the website.						
And you might consider merging reach the critical mass for things project to come together and ma	nist	ic that the				
Daniel Amelang						
1	Stephe	en wark waurer	i			

.....

14 Mar 2005	
I think TDI is a unique and very interesting project <b>16 Feb 2005</b> something for it	
So, where are w       10 Feb 2005         I still trust in open       Hello,         Luca Brivio       Hello,         9 Mar 2005       I'm a programmer, not something to keep the	nfectious / matches TDI). I am,
GNU started with RM Thank you kindly, Linux started with Lin Adam Huber You need someone g	
<ul> <li>people start sending patches</li> <li>I know this is chicken-egg, but someone needs to point this out, since I haven't seen the in the papers or the website.</li> <li>And you might consider merging into the bios.net effort mentioned already. Together, y reach the critical mass for things to take off. Consider this like when people jumped off project to come together and make linux work.</li> </ul>	you just might <b>mistic that the</b>
Daniel Amelang	

14 Mar 2005			
I think TDI is a unique and very interesting project <b>16 Feb 2005</b> something for it			
So, where are we 10 Feb 2005			
I still trust in open <sub>Hello,</sub>		lenecks are? Itial avenues to explore,	
Luca Brivio My name is Adam Huber and I am a medical student at UNSW in Sydney Austra I am interested in beginning research focused on tropical and infectious disease for underserved populations (A mission that seeminaly matches TDI).			
<b>9 Mar 2005</b> I'm a programmer, not a bioinformatician, but I stumbled across your site and thought I'd say something to keep the list active :)	s to		
GNU started with RMS. He gave us programming/administration tools to play with. Linux started with Linus. He released an operating system for us to play with. You need someone great in the field to release something for everyone to 'play with'. Then people start sending patches			
I know this is chicken-egg, but someone needs to point this out, since I haven't seen this brought up in the papers or the website.			
And you might consider merging into the bios.net effort mentioned already. Together, you just might reach the critical mass for things to take off. Consider this like when people jumped off the HURD project to come together and make linux work.	ic that the		
Daniel Amelang			
Stephen wark waurer			

	14 Mar 2005				
	I think TDI is a un something for it	ique and very inter	esting proje <b>16 Feb 2005</b>		
	So, where are we	10 Feb 2005			
	I still trust in open	Hello,			lenecks are? Itial avenues to explore,
	Luca Brivio	I am interested in	Huber and I am a medical student at UNSW in Sydne beginning research focused on tropical and infectious served populations (A mission that seemingly matches)		
l'm a	<b>ar 2005</b> a programmer, not ething to keep the	a bioinformatician,	but I stumbled across your site and thought I'd say	s to	
Linu <mark>You</mark>	ix started with Lii	nus. He released a reat in the field to	ogramming/administration tools to play with. an operating system for us to play with. In release something for everyone to 'play with'. Th	en	
l kno	ow this is chicken-e e papers or the we	egg, but someone i	19 Jan 2005		
read	h the critical mass	er merging into the for things to take of er and make linux		optimis	stic that the
Dan	iel Amelang		Stanhan Mark Maurar		
			Stephen Mark Maurer		

### **Science** @ Tropical Disease Initiative

www.tropicaldisease.org



Marc A. Marti-Renom



Depts. of Biopharmaceutical Sciences and Pharmaceutical Chemistry California Institute for Quantitative Biomedical Research University of California at San Francisco





Adapted from: - Nwaka & Ridley. (2003) Nature Reviews. Drug Discovery. 2:919 - Austin, Brady, Insel & collins. (2004) Science. 306:1138

# Drug Discovery pipeline





- + Completeness of genome projects (Malaria)
- + New and more complete biological databases
- + New software and computers (cheaper and faster)
- + Internet == more people
- Computational Biology **alone** is not enough
- TDI needs chemistry and biology! (How?)

# **TDI flowchart**



#### http://salilab.org/bioinformatics\_resources.shtml

Name	Type <sup>₫</sup>	World Wide Web address <sup>b</sup>
DATABASES		
CATH	S	http://www.biochem.ucl.ac.uk/bsm/cath/
DBAli	S	http://www.salilab.org/DBAli/
GenBank	S	http://www.ncbi.nlm.nih.gov/Genbank/GenbankSearch.html
GeneCensus	S	http://bioinfo.mbb.yale.edu/genome
MODBASE	S	http://salilab.org/modbase/
MSD	S	http://www.rcsb.org/databases.html
NCBI	S	http://www.ncbi.nlm.nih.gov/
PDB	S	http://www.rcsb.org/pdb/
PSI	S	http://www.nigms.nih.gov/psi/
Sacch3D	S	http://genome-www.stanford.edu/Sacch3D/
SCOP	S	http://scop.mrc-Imb.cam.ac.uk/scop/
TIGR	S	http://www.tigr.org/tdb/mdb/mdbcomplete.html
TrEMBL	S	http://srs.ebi.ac.uk/
FOLD ASSIGNM	ENT	
123D	S	http://123d.ncifcrf.gov/
3D-PSSM	S	http://www.sbg.bio.ic.ac.uk/~3dpssm/
BIOINBGU	S	http://www.cs.bgu.ac.il/~bioinbgu/
BLAST	S	http://www.ncbi.nlm.nih.gov/BLAST/
DALI	S	http://www2.ebi.ac.uk/dali/
FASS	S	http://bioinformatics.burnham-inst.org/FFAS/index.html
FastA	S	http://www.ebi.ac.uk/fasta3/
FRSVR	S	http://fold.doe-mbi.ucla.edu/
FUGUE	S	http://www-cryst.bioc.cam.ac.uk/~fugue/

# What CB can do?

Available computational biology resources for TDI

### **Protein-Ligand Universe**

Center for Computational Proteomics Research (CCPR)



# Databases



### Sequence search Profile based homology detection

AGHLRHA AGHL---

LAILRLPTAGNAR--AACLRLPTAGNARFC AGHLRATRCCLRLTTAGNAR

Ξ.

Sequence A: AGHLAHTRCELKLPTCRGNMSSRFC Sequence B: AGHLRHTRRCLRLPTAGNARFC AGCATHTRCELK-----MSSRFC AGHLAHPILELKLPTC---MSSRFC AGCGTHPILELK-----SSRFC AGHLAHTRCELKLPTCRGNMSSRFC







60



Marti-Renom etal. (2004) Prot. Sci. 13:1071

### Protein Structure Modeling ModPipe & ModWeb



# **Protein Structure Modeling**

Large-Scale prediction

Sequences	1,679,742
Modeled sequences	964,442
Models	2,947,461
ModWeb datasets	1,506
ModWeb Models	387,403

### **Protein Structure Modeling**

MODBASE (http://www.salilab.org/modbase/)

#### Search Page Home User Login ModBase Search Page ModWeb Modelling Server Help **Current Logins** MOD **Database of Comparative Protein Structure Models** Welcome to ModBase, a database of three-dimensional protein models calculated by comparative modeling. (Old ModBase Interface) General Information Search Statistics ModBase search form Project Pages Search type A Model(Default) Display type 🖬 Model Detail (graphical) 💌 -Documentation Authors and Acknowledgements All available datasets are selected Select specific dataset(s) Publications Todo List Search by properties Property 2 ALL **Related Resources** • Organism 🖬 ALL ▼ or Note: MODBASE contains theoretically calculated models, not experimentally Advanced search determined structures. The nodels may contair nificant errors.

#### Model Details

Mon	Home	User Login	ModBase Se	arch Page	ModWeb Modelling Server	Help
BASE					Cur	rent Logins
Sequence Info	ormation					
Primary Databa	ase Link 🗳	P43632 (KI2S4	HUMAN)			
Organism 🖬		<u>Homo sapiens</u>				
Annotation		killer cell immun associated trans	oglobulin-like recep cript 8) (nkat-8)de	tor 2ds4 precurs (p58 natural kille	or (mhc class ide nk cell receptor) (r r cell receptor clone cl-39) (p58 nk	natural killer
Sequence Leng	gth	304				
Model Informa	ation					
X			Sequence Model Co Sequence Identity E-Value Aodel Score Target Region Protein Length Template PDB Sode Template Region Dataset			
Filtered mode	Is for cur	rent sequence ( <u>S</u>	<u>how all models</u> )			
Cross-referen	ces					

#### Sequence Overview

See Id Foto History	hypothetical protein	Pseudomonas aeruginosa	3738
SeqId Fold HScore	hypothetical protein	<u>Escherichia coli</u>	1140
SegId Fold MScore	hypothetical protein spr1965	Streptococcus pneumoniae, Streptococcus pneumoniae	1038

#### Model Overview

£.	● □	Q8G8C7	hypothetical protein	<u>Pseudomonas</u> <u>aeruginosa</u>	4996	2089-2158	70	37.00	7e-14	1.00	<u>1dnyA</u>	8-78
<b>教</b> 後	•	Q8G8C7	hypothetical protein	<u>Pseudomonas</u> <u>aeruginosa</u>	4996	492-1017	526	36.00	1e-82	1.00	<u>1amuA</u>	19-529
Store Store	● □	<u>Q8G9W1</u>	hypothetical protein	<u>Escherichia coli</u>	1140	349-1135	787	35.00	0	1.00	<u>1r9dA</u>	6-783

### **Functional Annotation**

### Binding site prediction



# **Protein-Ligand Docking**



Paiva et al. (2001) Biochem. Biophys. Acta. **1545**:67-77 Shoichet, McGovern, Wei, Irwin (2002) Curr Opin Chem Biol. **6**:439-46

# **Protein-Ligand Docking**

### Successfully applied

Target	Best hit IC <sub>50</sub> (μM)	Docking program	Structure solved?	
Aldose reductase	4.3	Adam & Eve	No	
CDK4	44	Legend	Yes	
Matriptase	0.9	DOCK	Νο	
Bcl-2	10.4	DOCK	Νο	
Adenovirus protease	3.1	EUDOC	No	
AmpC	26 <sup>a</sup>	DOCK3.5.54	Yes	
Retinoic acid receptor	2	ICM	Νο	
TH receptor	1.5	ICM	No	
TGT	8.3	LUDI/ FlexX	Yes	
Carbonic anhydrase	0.0008	FlexX	Yes	
HPRTase	2.2 <sup>a</sup>	DOCK3.5.54	No	
Lysozyme cavity site	56 <sup>b</sup>	DOCK3.5.54	Yes	
H <sub>2</sub> picolinate reductase	7.2	FLOG	No	
PTP-1B	0.5	DOCK3.5.54	No	
Edema Factor	25 <sup>a</sup>	DOCK3.5.54	No	
CDK2	0.08	DOCK4	No	

Some recent docking successes (a. K<sub>i</sub>. b. K<sub>d</sub>.).

#### http://salilab.org/bioinformatics\_resources.shtml

Name	ne Type <sup>a</sup> World Wide Web address <sup>b</sup>			
DATABASES				
CATH	S	http://www.biochem.ucl.ac.uk/bsm/cath/		
DBAII	S	http://www.salilab.org/DBAli/		
GenBank	S	http://www.ncbi.nlm.nih.gov/Genbank/GenbankSearch.html		
GeneCensus	S	http://bioinfo.mbb.yale.edu/genome		
MODBASE	S	http://salilab.org/modbase/		
MSD	S	http://www.rcsb.org/databases.html		
NCBI	S	http://www.ncbi.nlm.nih.gov/		
PDB	S	http://www.rcsb.org/pdb/		
PSI	S	http://www.nigms.nih.gov/psi/		
Sacch3D	S	http://genome-www.stanford.edu/Sacch3D/		
SCOP	S	http://scop.mrc-Imb.cam.ac.uk/scop/		
TIGR	S	http://www.tigr.org/tdb/mdb/mdbcomplete.html		
TrEMBL	S	http://srs.ebi.ac.uk/		
FOLD ASSIGN	MENT			
123D	S	http://123d.ncifcrf.gov/		
3D-PSSM	S	http://www.sbg.bio.ic.ac.uk/~3dpssm/		
BIOINBGU	S	http://www.cs.bgu.ac.il/~bioinbgu/		
BLAST	S	http://www.ncbi.nlm.nih.gov/BLAST/		
DALI	S	http://www2.ebi.ac.uk/dali/		
FASS	S	http://bioinformatics.burnham-inst.org/FFAS/index.html		
FastA	S	http://www.ebi.ac.uk/fasta3/		
FRSVR	S	http://fold.doe-mbi.ucla.edu/		
FUGUE	S	http://www-cryst.bioc.cam.ac.uk/~fugue/		

### What CB has done?

Success stories in structure-based drug design...

# Examples

### HIV Proteinase inhibitors (1989)

#### Knowledge-based protein modelling and design.

Blundell T, et al Eur J Biochem. 1988 **15**:513

"A systematic technique for protein modelling that is applicable to the design of drugs, peptide vaccines and novel proteins is described. We have modelled an analogous protein, HIV viral proteinase on the basis of aspartic proteinases".

### X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes.

Lapatto et al Nature. 1989 Nov 16;342(6247):299-302.

"Knowledge of the tertiary structure of the proteinase from human immunodeficiency virus HIV-1 is important to the design of inhibitors that might possess antiviral activity and thus be useful in the treatment of AIDS. The conserved Asp-Thr/Ser-Gly sequence in retroviral proteinases suggests that they exist as dimers similar to the ancestor proposed for the pepsins."



HIV Proteinase structure

The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS.

Blundell et al Trends Biochem Sci. 1990 Nov;15(11):425-30.

"Analogies between the structures of HIV-1 proteinase and the mammalian enzyme renin have given **important clues** concerning the design of specific inhibitors that have antiviral activity."

### **Examples** mRNA Cap-1 Methyltransferase in SARS (2003)

Cell, Vol. 113, 701-702, June 13, 2003, Copyright ©2003 by Cell Press

#### Letter to the Editor



#### mRNA Cap-1 Methyltransferase in the SARS Genome

The 3D jury system has predicted the methyltransferase fold for the nsp13 protein of the SARS coronavirus. Based on the conservation of a characteristic tetrad of residues, the mRNA cap-1 methyltransferase function has been assigned to this protein, which has potential implications for antiviral therapy.

The latest outbreak of the severe acute respiratory syndrome (SARS) epidemic has led to thousands of potentially lethally infected patients and hundreds of deaths. These numbers are likely to rise, and the spreading disease is already causing major medical and economical concerns. Meanwhile, the SARS coronavirus identified as the pathogen responsible for the disaster has been isolated, and its genome sequenced (Marra et al., 2003; Rota et al., 2003).

We have applied the 3D jury meta predictor (Ginalski et al., 2003) to annotate the structure and function of proteins encoded by the viral positive-strand ssRNA. Novel fold recognition methods utilize the global network of independent structure prediction servers. Detection of patterns of structural similarity between diverse models is used to consistently select the correct fold from a set of borderline predictions. Such methods made a dramatic impact on the last critical assessment of protein structure prediction (CASP-5 experiment) conducted in the summer of 2002. One of the most interesting findings obtained during the SARS genome annotation process is a surprisingly reliable (3D jury score >100) assignment of the methyltransferase fold to the nsp13 (GI:30133975) domain located in the C-terminal part of the almost 7000 amino acid large pp1ab viral polyprotein (Figure 1). Standard sequence comparison tools such as PSI-BLAST or RPS-BLAST applied using the conserved domain database (Marchler-Bauer et al., 2003) failed to assign any function to this domain. The domain belongs to the ancient family of AdoMet-dependent ribose 2'-O-methyltransferases, which has been adapted by numerous viruses before the three domains of life evolved form the last universal common ancestor (LUCA) (Feder et al., 2003). The enzymatic role of the protein was confirmed by the presence of the conserved tetrad of residues K-D-K-E essential for mRNA cap-1 (mGpppNm) formation.

The mRNA cap methylation is found indispensable for efficient replication of many viruses (Bach et al., 1995; Woyciniuk et al., 1995; Vlot et al., 2002) and represents an active area for drug development. Nevertheless, direct inhibitors of the nsp13 enzyme may fail to suppress viral replication, as the cap-1 formation seems to be less critical than the preceding cap-0 (mGppN) formation (Latner et al., 2002; Wu and Guarino, 2003). The existence of the cap-1-forming enzyme in the genome would suggest that the virus also requires the AdoMet-dependent cap-0 methyltransferase. Both functions can be inhibited by carbocyclic analogs of adenosine, such as Neplanocin A or 3-deazaneplanocin A, which interfere with the AdoMet-AdoHcy metabolism of the host cell (De Clercq, 1998; Bray et al., 2002). Those compounds could complement other therapeutic strategies aimed at blocking enzymatic functions such as the RNAdependent RNA polymerase, the protease, or the helicase encoded by the SAR's virus.

Marcin von Grotthuss, Lucjan S. Wyrwicz, and Leszek Rychlewski\* Biolnf0Bank Institute Limanowskiego 24A 60-744 Poznan Poland

\*Correspondence: leszek@bioinfo.pl



Figure 1. 3D Model of the nsp13 Domain of the SARS Coronavirus pp1ab Polyprotein

This model is based on the reassigned (Bujnicki and Pychlewski, 2001) cap-1 methytransferase of the reovirus 24 proteint (reis [Reinisch et al., 2000). While other templates (feiz or 1eij0 obtained marginally higher 3D jury scores, the selected template had the lowest number of insertions and deletions. Side chains of the conserved tetrad of residues (k-D-K-E) essential for cap-1 methylation and the docked AdoMet octactor are shown. Four blocks of aligned motifs containing the conserved, function-specific residues are shown in upper right corner.

von Grotthuss M. et al. (2003) Cell **113** pp**701** Ginalski K, et al. (2003) Bioinformatics **19** pp**1**015

26

### **Examples** Genomic research on Malaria (2003)



Intraerythrocytic developmental cycle IDC





- 1. **Periodic and continuum** nature of the *P. falciparum* transcriptome (for at least 80% of the genes)
- 2. Potential for characterizing ~60% genes of unknown function

# Structure-based DD

### in companies...





#### Predix' Clinical Development Programs

SGX

Indication	Target	Drug Discovery	Lead Optimization	Pre-Clini	ical	IND	Phase I	Phase II
PRX-00023 Anxiety/Depression	5-HT1A				Ph	ase I Co	mplete	1H
<b>PRX-03140</b> Alzheimer's Disease	5-HT4					Phase I	1H	
<b>PRX-08066</b> Pulmonary Hypertension	5-HT2B		Pre-	Clinical			Q2	
			F	ebruary 21	005	2005	Anticipated	Milestones

Our lead product candidate Troxatyl,<sup>™</sup> is currently being evaluated in Phase I trials for the treatment of

relapsed AML and various solid tumors.

28



# TDI

### which problems we face?

# TDI scientific bottle necks ???

9 Mar 2005

GNU started with RMS. He gave us programming/administration tools to play with. Linux started with Linus. He released an operating system for us to play with. You need someone great in the field to release something for everyone to 'play with'.

**Daniel Amelang** 

- TOP-TEN scientific questions
- Road-Map to TOP-TEN answers
- Initial set of data and tools
- Initial set of contributors











# Acknowledgments

The Sali Lab Andrej Sali Frank Alber Ranyee Chiang Fred Davis **Damien Devos David Eramian** Libusha Kelly Michael F. Kim **Rachel Karchin Dmitry Korkin** M.S. Madhusudhan Eswar Narayanan Mark Peterson **Ursula Pieper** Min-yi Shen Maya Topf Ben Webb

**Tropical Disease Initiative** Stephen Maurer Arti Rai Andrej Sali

Ligand Docking John Irwin Brian Shoichet

Wiki site at NPG

Timo Hannay Declan Butler